GCM
TVTX icon

Graham Capital Management’s Travere Therapeutics TVTX Stock Holding History

Graham Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-466,998
Closed -$11.2M – 1592
2025
Q3 		$11.2M Buy
+466,998
New +$8.78M 0.18% 64
2025
Q2 		– Sell
-379,900
Closed -$6.81M – 1635
2025
Q1 		$6.81M Buy
379,900
+362,285
+2,057% +$7.35M 0.12% 93
2024
Q4 		$307K Buy
+17,615
New +$312K ﹤0.01% 920
2023
Q4 		– Sell
-16,071
Closed -$144K – 1346
2023
Q3 		$144K Sell
16,071
-19,287
-55% -$272K ﹤0.01% 906
2023
Q2 		$543K Buy
+35,358
New +$643K 0.02% 535
2022
Q1 		– Sell
-7,791
Closed -$241K – 1024
2021
Q4 		$241K Buy
+7,791
New +$219K 0.01% 396

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Graham Capital Management's TVTX Position: Q4 2025 in Review

Graham Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 466,998 shares — an estimated $11.2M sold.

Graham Capital Management first reported a position in TVTX in Q4 2021 and held it in 6 quarters. The position peaked at $11.2M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Graham Capital Management reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 466,998 Travere Therapeutics shares in Q4 2025, an estimated $11.2M.
  • Graham Capital Management first reported a position in Travere Therapeutics in Q4 2021 and held it in 6 quarters.
  • Graham Capital Management's Travere Therapeutics position peaked at $11.2M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.